A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
CorMedix Inc. (collectively, with our wholly owned subsidiaries, referred to herein as “we,” “us,” “our” or the “Company”) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Our primary focus has been commercializing DefenCath® (taurolidine and heparin), in the U.S., which we launched in 2024 in the hemodialysis setting. The name DefenCath is the U.S. proprietary name approved by the U.S. Food and Drug Administration (“FDA”).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 312M | 312M | 43M | - | - | - |
| Net Income | 163M | 163M | -18M | -46M | -30M | -28M |
| EPS | $2.04 | $2.04 | $-0.30 | $-0.91 | $-0.74 | $-0.75 |
| Free Cash Flow | 173M | 173M | -51M | -39M | -25M | -23M |
| ROIC | 61.5% | 101.9% | -21.2% | -66.1% | -53.9% | -44.9% |
| Gross Margin | 77.3% | 77.3% | 34.0% | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 150M | 150M | -22M | -49M | -31M | -29M |
| Operating Margin | 48.2% | 48.2% | -51.4% | - | - | - |
| ROE | 40.2% | 66.6% | -21.2% | -66.1% | -53.9% | -44.9% |
| Shares Outstanding | 80M | 80M | 60M | 51M | 40M | 38M |
CorMedix Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
CorMedix Inc. trades at 4.4x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. The company's 5-year average gross margin is 55.6%.
CorMedix Inc. (CRMD) has a current P/E ratio of 4.4, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
CorMedix Inc. (CRMD) has a 5-year average return on invested capital (ROIC) of -16.8%. This is below average and may indicate limited pricing power.
CorMedix Inc. (CRMD) has a market capitalization of $583M. It is classified as a small-cap stock.
CorMedix Inc. (CRMD) does not currently pay a regular dividend.
Based on historical P/E analysis, CorMedix Inc. (CRMD) appears cheap. The current P/E of 4.4 is 71% below its historical median of 15.0.
CorMedix Inc. (CRMD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CorMedix Inc. (CRMD) reported annual revenue of $312 million in its most recent fiscal year, based on SEC EDGAR filings.
CorMedix Inc. (CRMD) has a net profit margin of 52.3%. This is a strong margin indicating high profitability.
CorMedix Inc. (CRMD) generated $173 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CorMedix Inc. (CRMD) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
CorMedix Inc. (CRMD) reported earnings per share (EPS) of $2.04 in its most recent fiscal year.
CorMedix Inc. (CRMD) has a return on equity (ROE) of 66.6%. This indicates the company generates strong returns for shareholders.
CorMedix Inc. (CRMD) has a 5-year average gross margin of 55.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for CorMedix Inc. (CRMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CorMedix Inc. (CRMD) has a book value per share of $5.07, based on its most recent annual SEC filing.